GenSight Biologics Provides Summer 2026 Business and Clinical Development Updates
GenSight Biologics, a biopharmaceutical company specializing in the development and commercialization of innovative gene therapies for retinal neurodegenerative diseases and disorders of the central nervous system (CNS), has announced a series of business, manufacturing, clinical, and financial updates covering the summer of 2026. The company also confirmed the date for the publication of its financial statements for the first half of 2026.
Listed on Euronext under the ticker SIGHT and identified by ISIN FR0013183985, GenSight Biologics continues to advance its gene therapy programs, with a particular focus on therapies designed to address diseases affecting vision and the nervous system. The latest update highlights continued progress in the manufacturing transfer of GS010/LUMEVOQ®, ongoing clinical activities in France and other countries, and preparations to expand access to treatment through early access programs.
Manufacturing Transfer of GS010/LUMEVOQ® Progresses According to Plan
A key area of progress for GenSight Biologics during the summer has been the manufacturing development of GS010/LUMEVOQ®. The company reported that the manufacture of an engineering batch, an important step intended to confirm the successful transfer of the GS010/LUMEVOQ® manufacturing process to Catalent, has advanced according to plan.
The manufacturing transfer represents an important operational milestone for the company. Successful transfer of the production process is necessary to establish a reliable manufacturing pathway capable of producing the gene therapy consistently and at the required quality standards. Catalent is supporting the manufacturing activities as GenSight Biologics works to establish a repeatable process for future production.
One of the significant analytical results obtained from the engineering batch relates to the viral genome (vg) titer of the drug substance. Viral genome titer is an important manufacturing parameter because it provides an indication of the concentration of the therapeutic genetic material present in the drug substance.
According to GenSight Biologics, the vg titer measured in the engineering batch was within the company’s target specifications. This result provides further evidence that the manufacturing process transferred to Catalent is performing as expected.
The company also highlighted the results obtained from the engineering batch alongside data generated during earlier process development batches. In particular, the consistency of the vg titer observed during the upstream manufacturing process provides support for the reproducibility of the transferred production process.
The upstream stage is an important component of viral vector manufacturing because it involves the production of the viral vector carrying the therapeutic genetic material. Demonstrating reproducible yields during this stage is essential for establishing a dependable manufacturing platform.
GenSight Biologics said that the results obtained so far indicate that the process transferred to Catalent is capable of producing repeatable yields. This represents an encouraging development as the company moves toward the next phase of manufacturing activities.
The company expects to receive the complete set of drug substance test results toward the end of the summer. These results are expected to provide further confirmation regarding the successful transfer of the upstream portion of the manufacturing process.
Based on the progress achieved to date, GenSight Biologics has already initiated preparations for the manufacture of a Good Manufacturing Practice (GMP) batch. The planned GMP batch is intended to support product supply for the company’s early access programs.
The preparation of this batch is particularly relevant as GenSight Biologics continues to pursue opportunities to make GS010/LUMEVOQ® available to eligible patients through early access mechanisms. Establishing an appropriate GMP manufacturing supply is an important requirement for maintaining treatment availability as clinical and access activities progress.
REVISE Dose-Ranging Study Advances in France
GenSight Biologics also provided an update on its clinical activities, including the REVISE dose-ranging study being conducted in France at the request of the French health authority, the Agence nationale de sécurité du médicament et des produits de santé (ANSM).
The company confirmed that all remaining patients planned for the study have now been identified. The final treatment in the REVISE study is currently scheduled to take place in December 2026.
The completion of patient identification marks another step toward completing the planned clinical activities associated with the study. The REVISE program is intended to generate additional information concerning the appropriate dosing of the therapy and contribute to the broader clinical development strategy for GS010/LUMEVOQ®.
The timing of the final treatment means that the company expects clinical activities to continue through the end of 2026. Further developments will depend on the completion of the planned treatments and the subsequent evaluation of the resulting clinical data.
Named Patient Early Access Program Resumes in France
Alongside the REVISE study, GenSight Biologics is continuing to facilitate access to GS010/LUMEVOQ® through named patient early access programs.
During the summer period in France, applications for the named patient early access program, known as the AAC program, were temporarily paused. Following the summer break, the screening of potential patients has now resumed.
GenSight Biologics reported that some patients have already been treated under the program following the resumption of screening. The continuation of treatment through the AAC program provides an additional pathway for eligible patients to receive access to the therapy outside of a conventional clinical trial setting, subject to applicable regulatory and medical requirements.
The resumption of patient screening is therefore an important part of the company’s ongoing activities in France. GenSight Biologics expects the program to continue as patient applications and treatment processes move forward.
First Named Patient Treatment Completed in Israel
The company’s early access activities have also expanded geographically. GenSight Biologics confirmed that the first named patient early access treatment in Israel was administered in July 2026.
This represents an important milestone in the company’s efforts to broaden access to GS010/LUMEVOQ® internationally. The first treatment in Israel demonstrates progress in establishing early access pathways outside France and potentially creates additional opportunities for eligible patients in other territories.
GenSight Biologics further stated that treatments through paid early access programs in other countries are expected to take place during the remainder of 2026.
These activities are expected to complement the company’s ongoing clinical development and early access initiatives. The continued expansion of treatment programs will also depend on local regulatory frameworks, patient eligibility, manufacturing supply, and the availability of appropriate treatment centers.
Financial Position and Upcoming Half-Year Results
GenSight Biologics also provided an update regarding its financial activities. The company confirmed that payment associated with AAC treatments following the summer break has been received.
Revenue or payments associated with early access treatment programs can represent an important component of the company’s commercial and operational activities while it continues to advance its broader development programs. The receipt of payment following the resumption of AAC treatments provides an update on the financial side of the company’s early access activities.
In addition to this update, GenSight Biologics confirmed the date for publication of its financial statement covering the first half of 2026.
The company will publish its 2026 half-year financial statement after the close of the market on September 29, 2026, in line with its previously announced schedule. The financial release is expected to provide investors and stakeholders with further information regarding the company’s financial performance and position during the first six months of the year.
Ahead of the financial publication, GenSight Biologics will enter a quiet period beginning September 15, 2026. During this period, the company will limit communications relating to its financial performance in accordance with standard market practices surrounding financial reporting.
Continued Progress Toward 2026 Milestones
The latest update demonstrates that GenSight Biologics is continuing to make progress across several areas of its development and business strategy. Manufacturing activities for GS010/LUMEVOQ® are moving forward, with the engineering batch generating results within target specifications and supporting the reproducibility of the transferred production process.
At the same time, preparations for a GMP manufacturing batch are underway to support future product supply for early access programs. This manufacturing progress is particularly relevant as the company expands treatment availability and continues its clinical activities.
On the clinical side, all remaining patients planned for the REVISE dose-ranging study have been identified, with the final treatment expected in December 2026. The resumption of named patient early access screening in France and the first treatment in Israel further demonstrate the company’s continued efforts to provide access to GS010/LUMEVOQ®.
The company also anticipates additional paid early access treatments in other countries during the remainder of the year. Together, these activities indicate that GenSight Biologics is advancing multiple workstreams simultaneously, spanning manufacturing readiness, clinical development, patient access, and financial management.
The upcoming half-year financial statement on September 29 will provide an additional update on the company’s financial position and performance. Until then, the September 15 start of the quiet period will mark the beginning of the company’s pre-results communication restriction.
Overall, GenSight Biologics’ summer 2026 update reflects continued operational and clinical activity surrounding GS010/LUMEVOQ®. The successful progress of manufacturing transfer activities, advancement of the REVISE study, expansion of early access treatment, and planned GMP production represent important components of the company’s strategy as it moves toward the next stages of development and patient access.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.
GenSight Biologics’ lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. GS010 is currently in clinical development, has not to date been granted marketing authorization in France or any other jurisdiction, and is therefore not available commercially. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.